NcXHF

NONSURGICAL MANAGEMENT OF CERVICAL CANCER
corpus uteri invasion in cervical cancer patients treated by radiotherapy.
Int J Gynecol Cancer. 2006;16:623-630.
22. Narayan K, McKenzie AF, Hicks RJ, et al. Relation between FIGO
stage, primary tumor volume, and presence of lymph node metastases
in cervical cancer patients referred for radiotherapy. Int J Gynecol Cancer.
2003;13:657-663.
23. Schwarz JK, Grigsby PW, Dehdashti F, et al. The role of 18F-FDG PET
in assessing therapy response in cancer of the cervix and ovaries. J Nucl
Med. 2009;50 Supl 1:64S-73S.
24. Tod M, Meredith W. A dosage system for use in the treatment of cancer
of the uterine cervix. Br J Radiol. 1938;11:809-824.
25. Narayan K, van Dyk S, Bernshaw D, et al. Ultrasound guided conformal
brachytherapy of cervix cancer: survival, patterns of failure, and
late complications. J Gynecol Oncol. 2014;25:206-213.
26. Moore KN, Sill MW, Miller DS, et al. A phase I trial of tailored radiation
therapy with concomitant cetuximab and cisplatin in the treatment
of patients with cervical cancer: a gynecologic oncology group
study. Gynecol Oncol. 2012;127:456-461.
27. Schefter TE, Winter K, Kwon JS, et al. A phase II study of bevacizumab
in combination with defınitive radiotherapy and cisplatin chemotherapy
in untreated patients with locally advanced cervical carcinoma:
preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys. 2012;
83:1179-1184.
28. Schefter T, Winter K, Kwon JS, et al. RTOG 0417: effıcacy of bevacizumab
in combination with defınitive radiation therapy and cisplatin
chemotherapy in untreated patients with locally advanced cervical carcinoma.
Int J Radiat Oncol Biol Phys. 2014;88:101-105.
29. Mileshkin L, Paramanathan A, Kondalsamy-Chennakesavan S, et al.
Smokers with cervix cancer have more uterine corpus invasive disease
and an increased risk of recurrence after treatment with chemoradiation.
Int J Gynecol Cancer. 2014;24:1286-1291.
30. Bishop AJ, Allen PK, Klopp AH, et al. Relationship between low hemoglobin
levels and outcomes after treatment with radiation or
chemoradiation in patients with cervical cancer: has the impact of anemia
been Ooerstated? Int J Radiat Oncol Biol Phys. 2014;pii:S0360-
3016.
31. Thomas G, Ali S, Hoebers FJ, et al. Phase III trail to evaluate the effıcacy
of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin
vs above 10.0 g/dL without erythropoietin in anemic patients receiving
concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol.
2008;108:317-325.
32. Friedlander M, Grogan M, U.S. Preventative Services Task Force.
Guidelines for the treatment of recurrent and metastatic cervical cancer.
Oncologist. 2002;7:342-347.
33. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy
and pelvic radiation therapy compared with pelvic radiation therapy
alone as adjuvant therapy after radical surgery in high-risk earlystage
cancer of the cervix. J Clin Oncol 2000;18:1606-1613.
34. Kantardzić N, Beslija S, Begić D. [Comparative parameters of myelotoxicity
in patients treated with simultaneous chemotherapy and radiotherapy
or only radiotherapy]. Med Arh. 2004;58:19-22.
35. Dueñas-González A, Zarbá JJ, Patel F, et al. Phase III, open-label, randomized
study comparing concurrent gemcitabine plus cisplatin and
radiation followed by adjuvant gemcitabine and cisplatin versus concurrent
cisplatin and radiation in patients with stage IIB to IVA carcinoma
of the cervix. J Clin Oncol. 2011;29:1678-1685.
36. Thomas G. Are we making progress in curing advanced cervical cancer?
J Clin Oncol. 2011;29:1654-1656.
37. Ryu SY, Lee WM, Kim K, et al. Randomized clinical trial of weekly vs.
triweekly cisplatin-based chemotherapy concurrent with radiotherapy
in the treatment of locally advanced cervical cancer. Int J Radiat Oncol
Biol Phys. 2011;81:e577-e581.
38. Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer
Meta-Analysis Collaboration. Neoadjuvant chemotherapy for locally
advanced cervical cancer: a systematic review and meta-analysis of individual
patient data from 21 randomised trials. Eur J Cancer. 2003;39:
2470-2486.
39. McCormack M, Kadalayil L, Hackshaw A. A phase II study of weekly
neoadjuvant chemotherapy followed by radical chemoradiation for locally
advanced cervical cancer. Br J Cancer. 2013;108:2464-2469.
40. Wenzel L, DeAlba I, Habbal R, et al. Quality of life in long-term cervical
cancer survivors. Gynecol Oncol. 2005;97:310-317.
41. Ashing-Giwa KT, Tejero JS, Kim J, et al. Cervical cancer survivorship
in a population based sample. Gynecol Oncol. 2009;112:358-364.
42. Ashing-Giwa KT, Lim JW, Tang J. Surviving cervical cancer: does
health-related quality of life influence survival? Gynecol Oncol. 2010;
118:35-42.
43. Korfage IJ, Essink-Bot ML, Mols F, et al. Health-related quality of life
in cervical cancer survivors: a population-based survey. Int J RadiatOncol
Biol Phys. 2009;73:1501-1509.
44. Distefano M, Riccardi S, Capelli G, et al. Quality of life and psychological
distress in locally advanced cervical cancer patients administered
pre-operative chemoradiotherapy. Gynecol Oncol. 2008;111:144-150.
45. Bodurka DC, von Gruenigen VE. Women’s cancer survivorship: time
to gear up! Gynecol Oncol. 2012;124:377-378.
46. Weaver KE, Forsythe LP, Reeve BB, et al. Mental and physical healthrelated
quality of life among U.S. cancer survivors: population estimates
from the 2010 National Health Interview Survey. Cancer
Epidemiol Biomarkers Prev. 2012;21:2108-2117.
47. Lutgendorf SK, Anderson B, Rothrock N, et al. Quality of life and
mood in women receiving extensive chemotherapy for gynecologic
cancer. Cancer. 2000;89:1402-1411.
48. Bergmark K, Avall-Lundqvist E, Dickman PW, et al. Lymphedema and
bladder-emptying diffıculties after radical hysterectomy for early cervical
cancer and among population controls. Int J Gynecol Cancer.
2006;16:1130-1139.
49. Skjeldestad FE, Rannestad T. Urinary incontinence and quality of life
in long-term gynecological cancer survivors: a population-based
cross-sectional study. Acta Obstet Gynecol Scand. 2009;88:192-199.
50. Grover S, Hill-Kayser CE, Vachani C, et al. Patient reported late effects
of gynecological cancer treatment. Gynecol Oncol. 2012;124:399-403.
51. Abbott-Anderson K, Kwekkeboom KL. A systematic review of sexual
concerns reported by gynecological cancer survivors. Gynecol Oncol.
2012;124:477-489.
52. Ferrandina G, Mantegna G, Petrillo M, et al. Quality of life and emotional
distress in early stage and locally advanced cervical cancer patients:
a prospective, longitudinal study. Gynecol Oncol. 2012;124:389-
394.
53. Bodurka DC, Sun CC. Sexual function after gynecologic cancer. Obstet
Gynecol Clin North Am. 2006;33:621-630.
54. Lindau ST, Gavrilova N, Anderson D. Sexual morbidity in very long
term survivors of vaginal and cervical cancer: a comparison to national
norms. Gynecol Oncol. 2007;106:413-418.
55. Baze C, Monk BJ, Herzog TJ. The impact of cervical cancer on quality
of life: a personal account. Gynecol Oncol. 2008;109:S12-S14.
56. Sun C, Jhingran A, Gallegos J, et al. Longitudinal quality of life in medically
underserved women with locally advanced cervical cancer. Gynecol
Oncol. 2012;125:S50 (suppl 1; abstr 117).
57. Bodurka D, Sun C, Jhingran A, et al. A longitudinal evaluation of sexual
functioning and quality of life in cervical cancer survivors. Gynecol
Oncol. 2010;120:S81-S82 (suppl 1; abstr 187).
58. Wenzel L, Dogan-Ates A, Habbal R, et al. Defıning and measuring reproductive
concerns of female cancer survivors. J Natl Cancer Inst
Monogr. 2005;94-98.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e307